Antihistamines in Psoriasis

Swathi Shivakumar; Simon M. Mueller; Paul S. Yamauchi; Jeffrey M. Weinberg; Leon Kircik; Jacek C. Szepietowski; Mohamad Goldust

doi:10.36849/JDD.5966

Antihistamines in Psoriasis

Swathi Shivakumar, Simon M. Mueller, Paul S. Yamauchi, Jeffrey M. Weinberg, Leon Kircik, Jacek C. Szepietowski, Mohamad Goldust

Research output: Contribution to journal › Article › peer-review

Abstract

Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common and distressing symptom in psoriasis is itch, adding significantly to the burden of disease. Although histamine has historically not been considered a key itch mediator in psoriasis, there is some evidence from the literature that antihistamines may be effective to reduce itch in psoriasis. This review focuses on the role of antihistamines in the management of itch in psoriasis. The literature search included peer-reviewed articles published in English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) until January 2021 and by reference lists of respective articles.

Original language	English
Pages (from-to)	844-847
Number of pages	4
Journal	Journal of Drugs in Dermatology
Volume	20
Issue number	8
DOIs	https://doi.org/10.36849/JDD.5966
State	Published - Aug 2021

Access to Document

10.36849/JDD.5966

Cite this

@article{8ef49fade47b4a2cb4ddb5260ff1858e,

title = "Antihistamines in Psoriasis",

abstract = "Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common and distressing symptom in psoriasis is itch, adding significantly to the burden of disease. Although histamine has historically not been considered a key itch mediator in psoriasis, there is some evidence from the literature that antihistamines may be effective to reduce itch in psoriasis. This review focuses on the role of antihistamines in the management of itch in psoriasis. The literature search included peer-reviewed articles published in English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) until January 2021 and by reference lists of respective articles.",

author = "Swathi Shivakumar and Mueller, {Simon M.} and Yamauchi, {Paul S.} and Weinberg, {Jeffrey M.} and Leon Kircik and Szepietowski, {Jacek C.} and Mohamad Goldust",

year = "2021",

month = aug,

doi = "10.36849/JDD.5966",

language = "English",

volume = "20",

pages = "844--847",

journal = "Journal of Drugs in Dermatology",

issn = "1545-9616",

publisher = "Journal of Drugs in Dermatology",

number = "8",

}

TY - JOUR

T1 - Antihistamines in Psoriasis

AU - Shivakumar, Swathi

AU - Mueller, Simon M.

AU - Yamauchi, Paul S.

AU - Weinberg, Jeffrey M.

AU - Kircik, Leon

AU - Szepietowski, Jacek C.

AU - Goldust, Mohamad

PY - 2021/8

Y1 - 2021/8

N2 - Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common and distressing symptom in psoriasis is itch, adding significantly to the burden of disease. Although histamine has historically not been considered a key itch mediator in psoriasis, there is some evidence from the literature that antihistamines may be effective to reduce itch in psoriasis. This review focuses on the role of antihistamines in the management of itch in psoriasis. The literature search included peer-reviewed articles published in English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) until January 2021 and by reference lists of respective articles.

AB - Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common and distressing symptom in psoriasis is itch, adding significantly to the burden of disease. Although histamine has historically not been considered a key itch mediator in psoriasis, there is some evidence from the literature that antihistamines may be effective to reduce itch in psoriasis. This review focuses on the role of antihistamines in the management of itch in psoriasis. The literature search included peer-reviewed articles published in English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) until January 2021 and by reference lists of respective articles.

UR - http://www.scopus.com/inward/record.url?scp=85114522320&partnerID=8YFLogxK

U2 - 10.36849/JDD.5966

DO - 10.36849/JDD.5966

M3 - Article

C2 - 34397204

AN - SCOPUS:85114522320

SN - 1545-9616

VL - 20

SP - 844

EP - 847

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

IS - 8

ER -

Antihistamines in Psoriasis

Abstract

Access to Document

Fingerprint

Cite this